Erica N Evans

Landscape of Acquired Resistance to Osimertinib in <i>EGFR</i> -Mutant NSCLC and Clinical Validation of Combined EGFR and RET Inhibition with Osimertinib and BLU-667 for Acquired <i>RET</i> Fusion

Zofia Piotrowska, Hideko Isozaki, Jochen K. Lennerz et al. · Cancer Discovery · 2018 · 434 citations

Precision Targeted Therapy with BLU-667 for <i>RET</i>-Driven Cancers

Vivek Subbiah, Justin F. Gainor, Rami Rahal et al. · Cancer Discovery · 2018 · 386 citations

Avapritinib in advanced PDGFRA D842V-mutant gastrointestinal stromal tumour (NAVIGATOR): a multicentre, open-label, phase 1 trial

Michael C. Heinrich, Robin L. Jones, Margaret von Mehren et al. · The Lancet Oncology · 2020 · 294 citations

Tumor Biology, Gastrointestinal Oncology, Medicine +5

Inhibition of Btk with CC-292 Provides Early Pharmacodynamic Assessment of Activity in Mice and Humans

Erica N Evans, Richland Tester, Sharon Aslanian et al. · Journal of Pharmacology and Experimental Therapeutics · 2013 · 219 citations

A precision therapy against cancers driven by <i>KIT/PDGFRA</i> mutations

Erica N Evans, Alexandra K. Gardino, Joseph L. Kim et al. · Science Translational Medicine · 2017 · 209 citations